Amneal Pharmaceuticals (AMRX) vs Ionis Pharmaceuticals (IONS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amneal Pharmaceuticals (AMRX) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 89.7% versus a loss of 35.9%. Over five years, AMRX leads with a +248.4% price change compared with +25.8% for IONS. Ionis Pharmaceuticals is the larger company by market cap ($7.34 billion vs $6.84 billion), about 1.1 times the size.
Amneal Pharmaceuticals converts more of its revenue into profit, with a net margin of 2.4% versus -40.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRX | IONS |
|---|---|---|
| Share price | $19.65 | $44.16 |
| Market cap | $6.84B | $7.34B |
| 1-day change | -3.18% | +0.36% |
| YTD return | +55.95% | -44.18% |
| 1-year return | +89.67% | -35.94% |
| 5-year return | +248.40% | +25.81% |
| P/E ratio (TTM) | 41.81 | — |
| Forward P/E | 16.48 | — |
| EPS (TTM) | $0.47 | $-3.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.02B | $943.71M |
| Revenue growth (YoY) | +8.05% | +33.83% |
| Net income (latest FY) | $72.06M | $-381.39M |
| Gross margin | 36.88% | 98.31% |
| Operating margin | 13.05% | -40.45% |
| Net margin | 2.39% | -40.41% |
| 52-week high | $21.18 | $86.74 |
| 52-week low | $9.56 | $42.63 |
| Distance from 52-week high | -7.20% | -49.09% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +15.57% | +89.40% |
| Average volume | 2.22M | 3.79M |
| Shares outstanding | 348.30M | 166.18M |
| Employees | 8,700 | 1,480 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRX has outperformed IONS by 125.6 percentage points over the past year.
- Amneal Pharmaceuticals is more profitable, keeping 2.4 cents of every revenue dollar as net income versus -40.4 cents for Ionis Pharmaceuticals.
- Ionis Pharmaceuticals grew revenue faster in its latest fiscal year (+33.83% vs +8.05%).
About Amneal Pharmaceuticals
AMRX stock →Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,480 employees
AMRX vs IONS FAQ
Which is bigger, Amneal Pharmaceuticals or Ionis Pharmaceuticals?
Ionis Pharmaceuticals (IONS) is larger, with a market capitalization of $7.34B compared with $6.84B for Amneal Pharmaceuticals (AMRX).
Which stock has performed better over the past year, AMRX or IONS?
AMRX returned +89.67% over the past 12 months, compared with -35.94% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Amneal Pharmaceuticals and Ionis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.